Repetitive Transcranial Magnetic Stimulation (rTMS) was first approved the FDA in 2008. The indication was “for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.” Since then, the use of…
This content is for Monthly Membership and Yearly Membership members only.
Register
Register
Already a member? Log in here